Southwestern Oncology Group pretreatment risk criteria as predictive or prognostic factors in acute myeloid leukemia - Wikidata - awgldk - TriplyDB

Southwestern Oncology Group pretreatment risk criteria as predictive or prognostic factors in acute myeloid leukemia

Southwestern Oncology Group pretreatment risk criteria as predictive or prognostic factors in acute myeloid leukemia

http://www.wikidata.org/entity/Q33598706

about

Southwestern Oncology Group pretreatment risk criteria as predictive or prognostic factors in acute myeloid leukemia

http://www.wikidata.org/entity/Q33598706

description

2017 nî lūn-bûn

@nan

2017 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

name

Southwestern Oncology Group pr ...... tors in acute myeloid leukemia

@ast

Southwestern Oncology Group pr ...... tors in acute myeloid leukemia

@en

type

label

Southwestern Oncology Group pr ...... tors in acute myeloid leukemia

@ast

Southwestern Oncology Group pr ...... tors in acute myeloid leukemia

@en

prefLabel

Southwestern Oncology Group pr ...... tors in acute myeloid leukemia

@ast

Southwestern Oncology Group pr ...... tors in acute myeloid leukemia

@en

P1433

Q33598706-55C8FC55-2D47-475D-BE01-7F1A252544F7

P1476

Q33598706-24D343DC-EEB3-475E-9200-E8246AC1BEBF

P2093

Q33598706-0B3EF1F5-1793-41E8-90E5-5E4EE1AFD4C1

Q33598706-32058127-0259-4CFC-BE65-E2B2D348B8B8

Q33598706-39BF6B85-3C8B-4FEF-93AF-8742E66D2A38

Q33598706-6525B1AA-7D75-4EAC-A550-F90D0A243AC9

Q33598706-6DBFB335-F5D4-47B1-8287-0E6F3BF2D7D2

Q33598706-8ECFF47A-42A7-494D-A42D-E876378F5651

Q33598706-9811B199-8E89-4B9C-971F-2AA4EC1E003F

Q33598706-AC1DB03E-8213-40C3-8B33-A05E1C77E749

Q33598706-ADF009EE-F4D6-44AB-BB19-6738F02B2C08

Q33598706-CF526B28-9C79-4C27-8F55-DC29BDD905AB

P2860

Q33598706-0E8FF6FC-3469-4B64-8E80-193FAC3A5C2A

Q33598706-28EB165D-0F11-4357-8615-C05B59E15ED4

Q33598706-30701BD2-191F-495B-9CC9-4AB9178D5B90

Q33598706-308E8FE7-3F20-4920-A5BA-D7766888665B

Q33598706-3E4583AD-D208-4A4F-8E45-B1E5FEF3F789

Q33598706-466EE777-8FEE-483E-B636-DAF73B45CCE6

Q33598706-4C13C273-22C4-4F01-9354-C02C8860DD5E

Q33598706-52F0369E-0F4C-488A-962D-D1B89576C50C

Q33598706-562E8BB1-A28B-4988-8C80-D09AE8E238D1

Q33598706-5830DD42-8974-42F5-97F5-D864FC98B2AF

P304

Q33598706-B6152337-B728-4495-8C5F-6DCE112D3C0A

P31

Q33598706-553C4F21-2E92-477F-B95B-638E666B04AE

P356

Q33598706-3D136A2C-3BFA-4838-B470-A569E052BEFB

P433

Q33598706-777AA5A0-84BB-491D-BE11-FC5FFFDF54F1

P478

Q33598706-329C08B4-3218-4208-B66C-7059C9C1CC1F

P50

Q33598706-077606E8-1594-49C2-8E6D-3D6C3BCC95F0

Q33598706-A1603E4E-BAB1-40B8-804D-763B10E4397E

P577

Q33598706-BD97FA7A-508F-40DE-9B89-D38A0C08BD95

P698

Q33598706-DB1B2832-2BD5-47F7-9BC5-FC8F1CCFFE96

P932

Q33598706-535D8139-C162-40DC-9E6A-B2AC86EFB0CA

P356

P1433

Molecular and clinical oncology

P1476

Southwestern Oncology Group pr ...... tors in acute myeloid leukemia

@en

P2093

Ana Espirito Santo

http://www.w3.org/2001/XMLSchema#string

Angelo Martins

http://www.w3.org/2001/XMLSchema#string

Claudia Moreira

http://www.w3.org/2001/XMLSchema#string

Dulcineia Pereira

http://www.w3.org/2001/XMLSchema#string

Ilidia Moreira

http://www.w3.org/2001/XMLSchema#string

Isabel Ferreira

http://www.w3.org/2001/XMLSchema#string

Isabel Oliveira

http://www.w3.org/2001/XMLSchema#string

Jose Mariz

http://www.w3.org/2001/XMLSchema#string

Luis Leite

http://www.w3.org/2001/XMLSchema#string

Luisa Viterbo

http://www.w3.org/2001/XMLSchema#string

P2860

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

The World Health Organization (WHO) classification of the myeloid neoplasms

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia.

Leukaemogenesis: more than mutant genes

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.

P304

384-388

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MCO.2017.1134

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28451418

http://www.w3.org/2001/XMLSchema#string

P932

5403447

http://www.w3.org/2001/XMLSchema#string